Announcements Tomorrow’s quiz on NEJM paper Bring two questions about NEJM Exam I provided today.
Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE...
Transcript of Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE...
![Page 1: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/1.jpg)
Evaluating Clinical Risk and Guiding
management with SPECT Imaging
Raffaele Giubbini
Chair and Nuclear Medicine Unit
University & Spedali Civili – Brescia- Italy
![Page 2: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/2.jpg)
U.S. Congressional Budget Office.”Technological
Change and the Growth of Health Care Spending”
January 2008
![Page 3: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/3.jpg)
(Organization for Economic Cooperation and Development. New Y Times 19/06/2009)
![Page 4: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/4.jpg)
From 1996–2006, the total number of
inpatient cardiovascular operations and
procedures increased 30% from 5,444,000
to 7,191,000 annually. (AHA computation.)
(A Report From the American Heart Association Statistics Committee
and Stroke Statistics Subcommittee Circulation 2009;119;e21-e181)
Heart Disease and Stroke Statistics 2009
Update
![Page 5: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/5.jpg)
Heart Disease and Stroke Statistics 2009 Update
(A Report From the American Heart Association Statistics Committee
and Stroke Statistics Subcommittee Circulation 2009;119;e21-e181)
![Page 6: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/6.jpg)
(- Rosamond W et al Heart disease and stroke statistics-2007 update – Am Heart Ass
Statistics Committee and stroke Statistics Subcommittee. Circulation 2007;115:e69
- Feldman DN et al Am J Cardiol 2006; 98:1334)
PCI in USA
• In 2006 an estimated 1,313,00 PCI
• In 2004 more than 1 million coronary stent
procedures
• 85% of all PCI are undertaken electively in
pts with stable CAD
![Page 7: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/7.jpg)
Outcome as function of early strategy
conservative interventional p
TIMI IIIb (’89-’92; n=1473) . 6 w . 1 y
7.8% 12.2%
7.2% 10.8%
n.s. n.s.
VANQWISH (’93-’95; n=920)
. 1 m
. 1 y 5.6%
18.5% 10.4% 24.0%
0.01 0.02
OASIS (’95-’96; n= 7987)
. 7 d
. 6 m
4.4%
10.5%
4.9%
10.8%
n.s.
n.s.
FRISH II (’96-’97; n= 2457)
. 6 mi
. 1 y
12.1%
14.1%
9.4%
10.4%
0.03
0.001
TACTIS TIMI – trial (’97-’99; n=2220)
•. 30 d
• 6 m
7.4%
15.9%
10.5%
19.4%
0.009
0.025
![Page 8: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/8.jpg)
Seven-Year Outcome in the RITA 2 Trial: Coronary
Angioplasty vs Medical Therapy
( Henderson RA et al JACC 2003; 42: 1161)
![Page 9: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/9.jpg)
0
10
20
30
40
50
60
Death/MI Death Death/MI Death
isch guided
routine invasive
0
10
20
30
40
50
60
Death/MI Death Death/MI Death
isch guided
routine invasive
1 month 12 months
P=0.01
P=0.05
P=0.05
P=0.01
1 month 12 months
No history of prior MI Prior MI
( Heggunje PS et al Eur Heart J 2000; 21: 2014)
Early Invasive versus Ischaemia-guided Strategies in
the Management of non-Q wave Myocardial Infarction
Patients with and without Prior Myocardial Infarction
(Vanqwish trial)
![Page 10: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/10.jpg)
( BARI 2D study group N Engl J Med 2009; 360:2503)
A Randomized Trial of Therapies for Type 2 Diabetes and
Coronary Artery Disease
![Page 11: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/11.jpg)
![Page 12: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/12.jpg)
Are PCI benefits similar in
ACS and in stable CAD?
![Page 13: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/13.jpg)
Optimal Medical therapy with or without PCI
for Stable Coronary Disease
• 2287
( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 )
From 1999 to 2004
2287 Pts
Stenosis 70% in at least 1 coronary artery + objective evidence
of myocardial ischemia (2168 Pts)
Stenosis 80% and classic angina (119 Pts)
EXCLUSION CRITERIA:
persistent CCS class IV angina
markedly positive stress test
heart failure or cardiogenic shock
EF< 30%
cor. Anatomy not suitable for PCI
revascularization procedures within 6 months
![Page 14: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/14.jpg)
Optimal Medical therapy with or without PCI
for Stable Coronary Disease
( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 )
1149 PCI + medical therapy 1138 Medical Therapy
1077 PCI + Med. Therapy
Median Follow-up 4.6 y
Primary event rate
19%
Primary event rate
18.5%
![Page 15: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/15.jpg)
Optimal Medical therapy with or without PCI
for Stable Coronary Disease
( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 )
![Page 16: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/16.jpg)
Impact of Optimal Medical Therapy with or without
Percutaneous Coronary Intervention on Long-Term
Cardiovascular End Points in Patients with Stable
Coronary Artery Disease (from the COURAGE Trial)
( Boden WE et Am J Cardiol 2009; 104:1)
P=0.62
Tertiary End point:
Cardiac Death or MI
P=0.6
Tertiary End point:
Cardiac Death, MI or Hosp.for ACS
![Page 17: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/17.jpg)
Effect of PCI on Quality of Life in Patients
with Stable Coronary Disease
( Weintraub WS et al for the COURAGE Trial research Group NEJM 2008; 359:677 )
![Page 18: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/18.jpg)
Optimal Medical therapy with or without PCI
for Stable Coronary Disease
( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 )
PCI + OMT OMT
21.1% 32.6%
Revascularization during follow-up
![Page 19: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/19.jpg)
Is it possible to better
stratify these Patients
?
![Page 20: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/20.jpg)
Hierarchy of Evidence for CV Imaging
Optimized Test Effectiveness Srategy
Prognostic Utility
Symptom Benefit
Diagnostic Selectivity
IV Optimized Test Effectiveness Strategy
Comparative Effectiveness of
Imaging-Driven Strategy in RCT
Incremental Cost Effectiveness of
Imaging-Driven Strategies in RCT
III Prognostic Utility
Accuracy in Detecting MACE,
Independent Prediction
Exceeding Pre-Imaging, Cinical Hx
II Symptoms Benefit
Interaction of Imaging Risk
Markers, Presenting Symptoms
and Downstream symptom Burden
I Diagnostic Selectivity
Comparative Accuracy for Detecting
CAD
![Page 21: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/21.jpg)
Myocardial Perfusion Scintigraphy: the
Evidence
0
5
10
15
20
25
30
Death
or
MI
Ex-ECG MPI
normal
abnormal
P=N.S.
P<0.0001
( Underwood SR et al Eur J Nucl Med Mol Imaging 2004; 31: 261)
![Page 22: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/22.jpg)
# of pts F.U. yrs yr event rate high risk low risk
SPECT experience: 69,655 2.3(1.8-3.9) 3.0(1.7-4.3) 5.9(4.6-8.5) 0.85(0.6-1.2)
10 years
[median (25th–75th percentile)]
(Shaw LJ, Iskandrian AE. J Nucl Cardiol 2004; 11: 168 )
![Page 23: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/23.jpg)
PRETREATMENT
• Assessment of pretreatment gSPECT ischemia and its relationship to patient symptoms and angiographic disease burden
POSTTREATMENT
• Role of gSPECT in assessing recurrent chest-pain symptoms after the initial treatment
• Usefulness of gSPECT before and after therapy in assessing treatment effects.
Gated myocardial perfusion single photon
emission computed tomography in the clinical outcomes
utilizing revascularization and aggressive drug evaluation
(COURAGE) trial, Veterans Administration Cooperative study
no. 424
( Shaw LJ et al J Nucl Cardiol 2006; 13: 685)
![Page 24: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/24.jpg)
CABG PCI
(Elhendy, A. et al. J Nucl Cardiol. 2003;10: 615)
Risk stratification of patients after myocardial
revascularization by stress Tc - 99m Tetrofosmin myocardial
perfusion tomography.
![Page 25: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/25.jpg)
Optimal Medical Therapy With or Without Percutaneous
Coronary intervention to Reduce Ischemic Burden: Results
from the Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) Trial Nuclear
Substudy
( Shaw LJ et al Circulation 2008; 117: 1283)
![Page 26: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/26.jpg)
Prediction of Myocardial Infarction versus Cardiac Death by
Gated Myocardial Perfusion SPECT: Risk Stratification by the
Ammount of Stress-Induced Ischemia and the Postress
Ejection Fraction
( Sharir T et al J Nucl Med 2001; 42: 831)
![Page 27: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/27.jpg)
Prediction of Myocardial Infarction versus Cardiac
Death by Gated Myocardial Perfusion SPECT: Risk
Stratification by the Ammount of Stress-Induced
Ischemia and the Postress Ejection Fraction
0
0,5
1
1,5
2
2,5C
ard
iac D
eath
(%
/year)
No isch. Mild/Mod Large
EF > 50%
EF 30-50%
*
**
**
( Sharir T et al J Nucl Med 2001; 42: 831)
![Page 28: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/28.jpg)
Gated myocardial perfusion single photon
emission computed tomography in the clinical outcomes
utilizing revascularization and aggressive drug evaluation
(COURAGE) trial, Veterans Administration Cooperative study
no. 424
( Shaw LJ et al J Nucl Cardiol 2006; 13: 685)
![Page 29: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/29.jpg)
Optimal Medical Therapy With or Without Percutaneous
Coronary intervention to Reduce Ischemic Burden: Results
from the Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) Trial Nuclear
Substudy
( Shaw LJ et al Circulation 2008; 117: 1283)
![Page 30: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/30.jpg)
The economic consequences of available diagnostic
and prognostic strategies for the evaluation of stable
angina patients: an observational assessment of the
value of precatheterization ischemia. Economics of
Noninvasive Diagnosis (END) Multicenter Study Group.
0
3
6
9
12
De
ath
or
MI
(%)
LOW INTERMEDIATE HIGH
Conservative Invasive
0
3
6
9
12
Co
st/
Pati
en
t ($
1,0
00)
LOW INTERMEDIATE HIGH
* *
Outcomes Cost
( Shaw LJ et al J Am Coll Cardiol 1999;33:661)
![Page 31: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/31.jpg)
Outcomes of Patients with Stable Low-Risk Coronary
Artery Disease Receiving Medical- and PCI- Preceding
Therapies in Japan
(Tanihata S et al Circ J 2006; 70: 365)
![Page 32: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/32.jpg)
( American Heart Association - Herat disease and stroke statistics - 2005 Update)
Leading causes of Death for White Females
(U.S.A 2003)
![Page 33: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/33.jpg)
( American Heart Association
- Herat disease and stroke statistics - 2005 Update)
![Page 34: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/34.jpg)
Hachamovitch R, et al. J Am Coll Cardiol. 1996
Event Rates as Function of MPI With SPECT Results by
Gender
![Page 35: Evaluating Clinical Risk and Guiding management with SPECT ... · ( Boden WE et al for the COURAGE Trial research Group NEJM 2007; 356:1503 ) 1149 PCI + medical therapy 1138 Medical](https://reader034.fdocuments.us/reader034/viewer/2022050516/5fa0274d2bed19535a083ce5/html5/thumbnails/35.jpg)
Prognostic value of gated
myocardial pefusion SPECT.
(Shaw LJ, Iskandrian AE. J Nucl Cardiol 2004; 11: 168 )